Equities researchers at StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO – Get Free Report) in a report issued on Tuesday. The brokerage set a “strong-buy” rating on the medical research company’s stock.
Global Cord Blood Stock Performance
CO opened at $0.65 on Tuesday. The firm has a market cap of $79.01 million, a price-to-earnings ratio of 1.02 and a beta of 0.16. The stock has a fifty day moving average price of $0.94 and a 200-day moving average price of $1.17. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50.
About Global Cord Blood
Read More
- Five stocks we like better than Global Cord Blood
- A Deeper Look at Bid-Ask Spreads
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.